AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
update
/
details

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

NextEdge Admin

18 Dec 2024

2 min 28 sec

Cartherics Pty Ltd, a Melbourne-based biotechnology company specializing in immune cell therapies for cancer and other diseases, has been awarded a $300,000 G-Rex® grant. This grant will support clinical manufacturing of Cartherics’ lead product, CTH-401, for upcoming clinical trials.

The G-Rex® Grant Program, a $20 million initiative by ScaleReady, Wilson Wolf Manufacturing, and CellReady, accelerates cell and gene therapy advancements. Cartherics will use the grant to purchase equipment and reagents for R&D and manufacturing, focusing on platform assessment, method development, and upscaling CTH-401. The G-Rex system integration will also benefit the company’s pipeline by streamlining development processes.

Prof. Alan Trounson, CEO of Cartherics, emphasized the significance of integrating R&D and manufacturing under one roof, enabling seamless transition from preclinical research to clinical trials. “The G-Rex Grant is pivotal in advancing our innovative treatments for cancer and other diseases,” he said.

Dr. Damien Zanker, Cartherics’ Head of Clinical Manufacturing, highlighted the advantages of in-house manufacturing: reduced development time, cost savings, and leveraging internal expertise.

John Wilson, co-inventor of G-Rex and CEO of Wilson Wolf and CellReady, stated, “G-Rex is ideal for scaling Cartherics’ allo CAR-iNK cells. Their complete eradication of ovarian cancer cells in mice demonstrates their potential for human trials.”

Cartherics’ lead product, CTH-401, is an allogeneic CAR-NK cell therapy targeting TAG-72, a validated tumor marker. Derived from iPSCs, it features genetic enhancements for superior function, including immunosuppression-resistant modifications.
Cartherics is pioneering cell-based immunotherapies, developing CAR-T and CAR-NK products from genetically engineered iPSCs for cancer treatment.